Oligometastatic non-small-cell lung cancer: current treatment strategies

Patrick J Richard, Ramesh Rengan Department of Radiation Oncology, University of Washington, Seattle, WA, USA Abstract: The oligometastatic disease theory was initially described in 1995 by Hellman and Weichselbaum. Since then, much work has been performed to investigate its existence in ma...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Richard PJ, Rengan R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	oligometastatic non-small cell lung cancer oligoprogressive treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/12604e078d974966b21aec69246fa09b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:12604e078d974966b21aec69246fa09b
record_format	dspace
spelling	oai:doaj.org-article:12604e078d974966b21aec69246fa09b2021-12-02T00:41:07ZOligometastatic non-small-cell lung cancer: current treatment strategies1179-2728https://doaj.org/article/12604e078d974966b21aec69246fa09b2016-11-01T00:00:00Zhttps://www.dovepress.com/oligometastatic-non-small-cell-lung-cancer-current-treatment-strategie-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Patrick J Richard, Ramesh Rengan Department of Radiation Oncology, University of Washington, Seattle, WA, USA Abstract: The oligometastatic disease theory was initially described in 1995 by Hellman and Weichselbaum. Since then, much work has been performed to investigate its existence in many solid tumors. This has led to subclassifications of stage IV cancer, which could redefine our treatment approaches and the therapeutic outcomes for this historically “incurable” entity. With a high incidence of stage IV disease, non-small-cell lung cancer (NSCLC) remains a difficult cancer to treat and cure. Recent work has proven the existence of an oligometastatic state in NSCLC in terms of properly selecting patients who may benefit from aggressive therapy and experience long-term overall survival. This review discusses the current treatment approaches used in oligometastatic NSCLC and provides the evidence and rationale for each approach. The prognostic factors of many trials are discussed, which can be used to properly select patients for aggressive treatment regimens. Future advances in both molecular profiling of NSCLC to find targetable mutations and investigating patient selection may increase the number of patients diagnosed with oligometastatic NSCLC. As this disease entity increases, it is of utmost importance for oncologists treating NSCLC to be aware of the current treatment strategies that exist and the potential advantages/disadvantages of each. Keywords: oligometastatic, non-small-cell lung cancer, oligoprogressive, treatmentRichard PJRengan RDove Medical Pressarticleoligometastaticnon-small celllungcanceroligoprogressivetreatmentNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 7, Pp 129-140 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	oligometastatic non-small cell lung cancer oligoprogressive treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	oligometastatic non-small cell lung cancer oligoprogressive treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Richard PJ Rengan R Oligometastatic non-small-cell lung cancer: current treatment strategies
description	Patrick J Richard, Ramesh Rengan Department of Radiation Oncology, University of Washington, Seattle, WA, USA Abstract: The oligometastatic disease theory was initially described in 1995 by Hellman and Weichselbaum. Since then, much work has been performed to investigate its existence in many solid tumors. This has led to subclassifications of stage IV cancer, which could redefine our treatment approaches and the therapeutic outcomes for this historically “incurable” entity. With a high incidence of stage IV disease, non-small-cell lung cancer (NSCLC) remains a difficult cancer to treat and cure. Recent work has proven the existence of an oligometastatic state in NSCLC in terms of properly selecting patients who may benefit from aggressive therapy and experience long-term overall survival. This review discusses the current treatment approaches used in oligometastatic NSCLC and provides the evidence and rationale for each approach. The prognostic factors of many trials are discussed, which can be used to properly select patients for aggressive treatment regimens. Future advances in both molecular profiling of NSCLC to find targetable mutations and investigating patient selection may increase the number of patients diagnosed with oligometastatic NSCLC. As this disease entity increases, it is of utmost importance for oncologists treating NSCLC to be aware of the current treatment strategies that exist and the potential advantages/disadvantages of each. Keywords: oligometastatic, non-small-cell lung cancer, oligoprogressive, treatment
format	article
author	Richard PJ Rengan R
author_facet	Richard PJ Rengan R
author_sort	Richard PJ
title	Oligometastatic non-small-cell lung cancer: current treatment strategies
title_short	Oligometastatic non-small-cell lung cancer: current treatment strategies
title_full	Oligometastatic non-small-cell lung cancer: current treatment strategies
title_fullStr	Oligometastatic non-small-cell lung cancer: current treatment strategies
title_full_unstemmed	Oligometastatic non-small-cell lung cancer: current treatment strategies
title_sort	oligometastatic non-small-cell lung cancer: current treatment strategies
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/12604e078d974966b21aec69246fa09b
work_keys_str_mv	AT richardpj oligometastaticnonsmallcelllungcancercurrenttreatmentstrategies AT renganr oligometastaticnonsmallcelllungcancercurrenttreatmentstrategies
_version_	1718403539933331456

Oligometastatic non-small-cell lung cancer: current treatment strategies

Ejemplares similares